Billiontoone (NASDAQ:BLLN) CTO David Tsao Sells 10,000 Shares of Stock

Posted by Brian Himes on Aug 12th, 2026

Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) CTO David Tsao sold 10,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $92.86, for a total value of $928,600.00. Following the completion of the sale, the chief technology officer owned 1,000 shares of the company’s stock, valued at approximately $92,860. This trade represents a 90.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $102.27, for a total value of $2,045,400.00.

Billiontoone Trading Down 0.5%

Shares of BLLN traded down $0.49 during mid-day trading on Wednesday, hitting $97.45. 522,419 shares of the company’s stock traded hands, compared to its average volume of 537,016. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $4.48 billion and a P/E ratio of 139.21. The business’s 50-day moving average price is $116.72 and its 200-day moving average price is $94.50. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $150.44.

Billiontoone (NASDAQ:BLLN – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. The company had revenue of $109.45 million during the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. As a group, sell-side analysts forecast that Billiontoone, Inc. will post 0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Billiontoone

Hedge funds have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA purchased a new stake in Billiontoone in the fourth quarter worth about $13,373,000. Baillie Gifford & Co. purchased a new position in shares of Billiontoone during the fourth quarter valued at approximately $103,786,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Billiontoone in the 4th quarter worth approximately $1,348,000. UBS Group AG purchased a new stake in shares of Billiontoone in the 4th quarter worth approximately $2,586,000. Finally, Renaissance Capital LLC purchased a new stake in shares of Billiontoone in the 4th quarter worth approximately $201,000.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. cut their target price on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. BTIG Research cut their price objective on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Guggenheim assumed coverage on Billiontoone in a report on Monday, June 29th. They set a “buy” rating and a $125.00 target price on the stock. Finally, Wall Street Zen lowered Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Billiontoone has a consensus rating of “Moderate Buy” and a consensus target price of $126.71.

Get Our Latest Analysis on Billiontoone

Billiontoone Company Profile

(Get Free Report)

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.